Ebba Nexø
About
In The Last Decade
Ebba Nexø
388 papers receiving 13.9k citations
Hit Papers
Peers
Comparison fields: 5 of 159
- Rheumatology 5.9k
- Molecular Biology 5.3k
- Surgery 2.2k
- Oncology 1.8k
- Hematology 1.5k
Countries citing papers authored by Ebba Nexø
This map shows the geographic impact of Ebba Nexø's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ebba Nexø with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ebba Nexø more than expected).
Fields of papers citing papers by Ebba Nexø
This network shows the impact of papers produced by Ebba Nexø. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ebba Nexø. The network helps show where Ebba Nexø may publish in the future.
Co-authorship network of co-authors of Ebba Nexø
This figure shows the co-authorship network connecting the top 25 collaborators of Ebba Nexø. A scholar is included among the top collaborators of Ebba Nexø based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ebba Nexø. Ebba Nexø is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 3 | |
| 3 | 3 | |
| 4 | 26 | |
| 5 | Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. | 18 |
| 6 | 73 | |
| 7 | 61 | |
| 8 | 66 | |
| 9 | 114 | |
| 10 | 10 | |
| 11 | 50 | |
| 12 | A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. | 99 |
| 13 | Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. | 59 |
| 14 | 63 | |
| 15 | Guidelines for the presentation of experimental protocols and reports, data documentation and data storage in basic health research.Danish Medical Research Council and Danish Committee on Scientific Dishonesty. | 0 |
| 16 | 12 | |
| 17 | 120 | |
| 18 | 46 | |
| 19 | 5 | |
| 20 | 68 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.